drugset / Trial / NCT03352323

An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea

NCT03352323

Phase 3 Completed 50 enrolled Padagis LLC
NaSingle-groupOpen-labelTreatment

Summary

the study will measure the decrease in redness on the face of rosacea subjects

Timeline

Start
2017-10-18
Primary completion
2017-12-06
Completion
2018-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymetazoline Other / unclassified 1 % Topical

Indications